Resources
Proteomics Databases
Metabolomics Databases
-
• Applications of Top-Down Proteomics for Cancer Biomarker Discovery
Tumor biomarkers are critical molecular indicators for cancer diagnosis and therapeutic decision-making and have long been supported by proteomics technologies. However, cancer is a highly heterogeneous disease, and its key proteins often exist as diverse proteoforms characterized by extensive post-translational modifications (PTMs) and sequence variants. These subtle molecular features are frequently overlooked by Bottom-Up proteomics, thereby limiting both the depth and precision of biomarker discov......
-
In the investigation of proteome complexity, the comprehensive characterization of protein proteoforms remains a central challenge in biomedical research. Proteoforms, encoded by the same gene, exhibit substantial structural and functional heterogeneity arising from alternative splicing, post-translational modifications (PTMs), and point mutations. Accurate identification of these proteoforms is not only fundamental to elucidating disease mechanisms and facilitating targeted drug development, but also......
-
• NGS Sequencing De Novo: When Short-Read Data Are Enough and When You Need a Hybrid Assembly Design
Technical guide for NGS Sequencing De Novo: When Short-Read Data Are Enough and When You Need a Hybrid Assembly Design.
-
• De Novo Sequencing by ESI-MS/MS: Troubleshooting Fragment Coverage and Sequence Ambiguity
Technical guide for De Novo Sequencing by ESI-MS/MS: Troubleshooting Fragment Coverage and Sequence Ambiguity.
-
Technical guide for De Novo Assembly Shotgun Sequencing: What Affects Contig Quality, Repeat Resolution, and Assembly Usability.
-
• Protein Sequencing Service Cost Guide: Price, Timeline, and Deliverables
Protein sequencing cost is shaped by more than the number of samples. A simple protein identification project from a clean gel band is very different from de novo sequencing of a low-abundance protein with no reliable database. A terminal residue check is different from a primary-structure evidence package for a biologic. The same keyword can describe very different scopes of work.
-
• Antibody Sequencing Sample Problems and How to Avoid Failed Results
Many sequencing failures begin before the instrument run. The sample may contain more than one antibody. The hybridoma may be unstable. RNA may be degraded. The antibody concentration may be lower than expected. Buffer additives may interfere with digestion, amplification, or downstream analysis. These issues do not always make sequencing impossible, but they can reduce coverage, increase ambiguity, and delay interpretation.
-
• Antibody Sequencing Methods Compared: MS, PCR, and Edman
Choosing a sequence recovery method is rarely a purely technical preference. It depends on the material available, the sequence information already known, and the decision the data must support. A hybridoma recovery project, a purified antibody rescue project, and a biosimilar characterization project can all involve sequencing, but they do not need the same workflow.
-
• Antibody Sequencing: How It Works and When to Use It
Antibody projects often reach a point where binding data alone is not enough. A monoclonal antibody may show strong activity in ELISA or cell assays, yet the team may not know the exact heavy-chain and light-chain sequences. A legacy hybridoma may lose productivity. A purified antibody may come from an old inventory with incomplete records. In each case, the sequence becomes the bridge between a useful binder and a reproducible research or development asset.
-
• Antibody Sequencing Cost Guide: What Drives Price and Turnaround
Project cost is shaped by more than the number of samples. A simple hybridoma sequence recovery project and a difficult de novo sequencing project from limited purified protein require different levels of preparation, instrumentation, assembly, and review. The same keyword can describe very different scopes of work.
How to order?
